600056 China Meheco Group
- 11.65
- +0.89+8.27%
China Meheco Group News
China Pharmaceutical (600056) 2020 Third Quarter Report Review: Q3 performance is in line with expectations, the integrated two-wing strategy is progressing steadily
China Pharmaceutical (600056) 2020 Interim Report Review: International trade has increased dramatically, and industry and commerce have basically recovered
China Pharmaceutical (600056) 2020 China News Review: steady performance growth is in line with expectations and the two-wing strategy continues to advance.
China Pharmaceutical (600056) 2020 Semi-Annual Report Review: Hospital Channels Are Waiting to Resume, Multiple New Varieties Approved
China Pharmaceutical (600056): the performance improvement is expected under the pressure of the second and third terminals of the industrial plate.
Comments on major issues of China Pharmaceutical (600056): 2.2 billion heavy acquisition of industrial, commercial and trade integrated assets the investment income is expected to increase by 142 million yuan in 2020.
China Pharmaceutical (600056) 2019 Interim Report Review - Performance pressure is basically in line with expectations, the integrated two-wing strategy continues to advance
China Pharmaceutical (600056) Research Report: Actively Responding to Industry Challenges and Continuing to Promote Business Integration
Chinese Medicine (600056): Commerce, international trade pick up, industry meets challenges
Comments on China Pharmaceutical (600056) 2018 Annual report: the performance of marketing system transformation is lower than expected
中国医药(600056)季报点评：收入增速有所回升 继续推进商业网络布局
中国医药(600056)季报点评：业绩表现平稳 三大业务板块稳定增长
中国医药(600056)三季报点评：收入端开始提速 业绩符合预期
中国医药(600056)季报点评：营收增长加速 工业板块承压
中国医药(600056)季报点评：工业尚在营销整合阵痛期 商业走出底部
中国医药(600056)半年报点评：工、商、贸业务盈利能力提升
中国医药(600056)中报点评：工业板块持续发力 商业板块推进区域扩张
中国医药(600056)中报点评：盈利能力提升 业绩符合预期
中国医药(600056)半年报点评：收入端增速放缓 业务与产品结构优化带动利润增长
中国医药(600056)中报点评：业绩完全符合我们预期 二季度恢复较快增长
Analysis
Price Target
No Data
No Data